ReviewBest practice & research. Clinical endocrinology & metabolism2023
Statins and diabetes: What are the connections?
Review in Best practice & research. Clinical endocrinology & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06551298 (Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action.Molecules (Basel, Switzerland) · 2024Pooled it
- [Biophysical and biochemical differences in CADIMSS patients: Different therapeutic managements].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users.Human genomics · 2026Article
- PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway.International journal of molecular sciences · 2026Article
- Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank.Journal of the American Heart Association · 2026Article
- Diabetes is associated with reduced grip strength: A cross-sectional study of medical check-up results in Japanese seniors.Journal of diabetes investigation · 2026Article
- Statin Induced New-onset Diabetes Mellitus - A Narrative Review.Journal of community hospital internal medicine perspectives · 2026Review
- Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study.Cardiovascular diabetology · 2025Article
- Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.International journal of molecular sciences · 2025Review
- Protein prenylation in islet β-cell function in health and metabolic stress.Biochemical pharmacology · 2025Review
- From cholesterol to glucose: uncovering how statins induce β-cell dysfunction to promote type 2 diabetes.The Journal of endocrinology · 2025Review
- Nano-Encapsulated Phytosterols Ameliorate Hypercholesterolemia in Mice via Dual Modulation of Cholesterol Metabolism Pathways.Nutrients · 2025Article
- An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease.Frontiers in pharmacology · 2025Review
- Statins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity.Journal of cardiovascular development and disease · 2024Review
- Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events.Drugs & aging · 2024Review
- Atorvastatin ameliorated myocardial fibrosis by inhibiting oxidative stress and modulating macrophage polarization in diabetic cardiomyopathy.World journal of diabetes · 2024Article
- Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?Diabetologia · 2024Review
- Prostate Cancer and the Mevalonate Pathway.International journal of molecular sciences · 2024Review
- Can acetate via FFA receptors contribute to the diabetogenic effect of statins?Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Statins and risk of type 2 diabetes: mechanism and clinical implications.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Randomized trials suggest moderate-intensity statins increase type 2 diabetes risk by around 11% with a potential further 12% moving to high-intensity statins, such that high intensity may increase risk by 20% or more relative to placebo. These data translate into one extra diabetes case per 100-200 statin recipients over 5 years, with ∼10-fold greater benefits on major vascular outcomes. The underlying mechanisms for diabetes harm are not clear but could include modest weight gain (noted in randomized trials), or, speculatively, beta cell harm. Concordant genetic studies link HMG CoA Reductase inhibition to diabetes risk and weight gain. Patients should be warned about a slight diabetes risk when prescribed statin and told that modest lifestyle improvements can i) nullify diabetes risk, and ii) improve cardiovascular risks beyond statins. Doctors should also measure glycemia status post statin commencement, most commonly with HbA1c, and tailor lifestyle advice and care dependent on the results.
Indexed as
Identifiers
36858834What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.